These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 30529689)
1. Loperamide overcomes the resistance of colon cancer cells to bortezomib by inducing CHOP-mediated paraptosis-like cell death. Kim IY; Shim MJ; Lee DM; Lee AR; Kim MA; Yoon MJ; Kwon MR; Lee HI; Seo MJ; Choi YW; Choi KS Biochem Pharmacol; 2019 Apr; 162():41-54. PubMed ID: 30529689 [TBL] [Abstract][Full Text] [Related]
2. Lercanidipine Synergistically Enhances Bortezomib Cytotoxicity in Cancer Cells via Enhanced Endoplasmic Reticulum Stress and Mitochondrial Ca Lee AR; Seo MJ; Kim J; Lee DM; Kim IY; Yoon MJ; Hoon H; Choi KS Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817163 [TBL] [Abstract][Full Text] [Related]
3. Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis. Lee DM; Kim IY; Seo MJ; Kwon MR; Choi KS Exp Mol Med; 2017 Aug; 49(8):e365. PubMed ID: 28798402 [TBL] [Abstract][Full Text] [Related]
4. Co-targeting translation and proteasome rapidly kills colon cancer cells with mutant RAS/RAF via ER stress. Li X; Li M; Ruan H; Qiu W; Xu X; Zhang L; Yu J Oncotarget; 2017 Feb; 8(6):9280-9292. PubMed ID: 28030835 [TBL] [Abstract][Full Text] [Related]
5. ISRIB plus bortezomib triggers paraptosis in breast cancer cells via enhanced translation and subsequent proteotoxic stress. Lee DM; Seo MJ; Lee HJ; Jin HJ; Choi KS Biochem Biophys Res Commun; 2022 Mar; 596():56-62. PubMed ID: 35114585 [TBL] [Abstract][Full Text] [Related]
6. Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells. Wada N; Kawano Y; Fujiwara S; Kikukawa Y; Okuno Y; Tasaki M; Ueda M; Ando Y; Yoshinaga K; Ri M; Iida S; Nakashima T; Shiotsu Y; Mitsuya H; Hata H Int J Oncol; 2015 Mar; 46(3):963-72. PubMed ID: 25530098 [TBL] [Abstract][Full Text] [Related]
7. Effect of proteasome inhibitors on canine lymphoma cell response to CHOP chemotherapy in vitro. Prevedel NE; Mee MW; Wood GA; Coomber BL Vet Comp Oncol; 2024 Mar; 22(1):96-105. PubMed ID: 38237918 [TBL] [Abstract][Full Text] [Related]
8. Bortezomib sensitizes human osteosarcoma cells to adriamycin-induced apoptosis through ROS-dependent activation of p-eIF2α/ATF4/CHOP axis. Xian M; Cao H; Cao J; Shao X; Zhu D; Zhang N; Huang P; Li W; Yang B; Ying M; He Q Int J Cancer; 2017 Sep; 141(5):1029-1041. PubMed ID: 28524233 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors. Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737 [TBL] [Abstract][Full Text] [Related]
11. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities. Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668 [TBL] [Abstract][Full Text] [Related]
12. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331 [TBL] [Abstract][Full Text] [Related]
13. SNIPER(TACC3) induces cytoplasmic vacuolization and sensitizes cancer cells to Bortezomib. Ohoka N; Nagai K; Shibata N; Hattori T; Nara H; Cho N; Naito M Cancer Sci; 2017 May; 108(5):1032-1041. PubMed ID: 28192613 [TBL] [Abstract][Full Text] [Related]
14. PSMD14 Targeting Triggers Paraptosis in Breast Cancer Cells by Inducing Proteasome Inhibition and Ca Lee HJ; Lee DM; Seo MJ; Kang HC; Kwon SK; Choi KS Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269789 [TBL] [Abstract][Full Text] [Related]
15. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors. Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283 [TBL] [Abstract][Full Text] [Related]
16. GRP78 inhibition enhances ATF4-induced cell death by the deubiquitination and stabilization of CHOP in human osteosarcoma. Luo J; Xia Y; Luo J; Li J; Zhang C; Zhang H; Ma T; Yang L; Kong L Cancer Lett; 2017 Dec; 410():112-123. PubMed ID: 28947141 [TBL] [Abstract][Full Text] [Related]
17. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma. Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656 [TBL] [Abstract][Full Text] [Related]
18. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Nawrocki ST; Carew JS; Dunner K; Boise LH; Chiao PJ; Huang P; Abbruzzese JL; McConkey DJ Cancer Res; 2005 Dec; 65(24):11510-9. PubMed ID: 16357160 [TBL] [Abstract][Full Text] [Related]
19. Pyrrolidine dithiocarbamate reverses Bcl-xL-mediated apoptotic resistance to doxorubicin by inducing paraptosis. Park SS; Lee DM; Lim JH; Lee D; Park SJ; Kim HM; Sohn S; Yoon G; Eom YW; Jeong SY; Choi EK; Choi KS Carcinogenesis; 2018 Mar; 39(3):458-470. PubMed ID: 29329420 [TBL] [Abstract][Full Text] [Related]
20. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib. Malek E; Driscoll JJ Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]